{"id":"lzm012","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed clinical trial data or published mechanism information, the precise molecular target and pharmacological action of LZM012 cannot be reliably determined. Phase 3 status indicates it has progressed through early safety and efficacy testing, but full mechanistic details may remain proprietary or under regulatory review.","oneSentence":"LZM012 is an investigational therapeutic agent in phase 3 development by Livzon Pharmaceutical Group, but its specific mechanism of action is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:57.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06110676","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of LZM012","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2023-08-21","conditions":"Psoriasis","enrollment":918}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LZM012","genericName":"LZM012","companyName":"Livzon Pharmaceutical Group Inc.","companyId":"livzon-pharmaceutical-group-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}